Three Late-Stage Leukemia Company Previews for ASCO

Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.

Investment Opportunities with Five Frontline Therapies for AML

Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow.  Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet.  In AML, abnormal b